Graft Versus Host Disease
Showing 1 - 25 of 178
Graft Vs Host Disease, Graft-versus-host-disease, GVHD Trial in Saint Louis (Ruxolitinib)
Not yet recruiting
- Graft Vs Host Disease
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Aug 18, 2023
Mapping for Detection of Chronic Lung Injury in Hematopoietic
Recruiting
- Chronic Lung Disease
- +2 more
-
Ann Arbor, MichiganThe University of Michigan Cancer Center
May 9, 2023
GVHD, Postbiotics, Butyrate Trial in Seoul (sodium butyrate)
Recruiting
- Graft Versus Host Disease
- +2 more
- sodium butyrate
-
Seoul, Korea, Republic ofSoonchunhyang University Seoul Hospital
Apr 11, 2023
GVHD Trial in Chicago (Expressive Writing)
Not yet recruiting
- Graft Versus Host Disease
- Expressive Writing
-
Chicago, IllinoisDepartment of Dermatology, Northwestern University Feinberg Scho
Jan 12, 2023
Immunodeficiency, Immunosuppression, HIV Trial in La Jolla (Access to Cue Health COVID-19 Remote testing and treatment for
Recruiting
- Immunodeficiency
- +8 more
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
-
La Jolla, CaliforniaScripps Research
Dec 22, 2022
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial
Active, not recruiting
- Acute Leukemia
- +14 more
- Busulfan
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 18, 2022
GVHD Trial in Cleveland (Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP))
Not yet recruiting
- Graft Versus Host Disease
- Allogeneic mesenchymal stromal cells (MSCs)
- Extracorporeal photopheresis (ECP)
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Nov 14, 2022
GVHD Trial in Tampa (Cultured Treg cells)
Completed
- Graft Versus Host Disease
- Cultured Treg cells
-
Tampa, FloridaH Lee Moffitt Cancer Center
Nov 2, 2022
Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)
Completed
- Chronic Myeloproliferative Disorders
- +5 more
- sargramostim
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 3, 2022
GVHD, Hematopoietic/Lymphoid Cancer Trial in Winston-Salem (fludarabine phosphate, busulfan, cyclophosphamide)
Active, not recruiting
- Graft Versus Host Disease
- Hematopoietic/Lymphoid Cancer
- fludarabine phosphate
- +5 more
-
Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
Aug 5, 2022
GVHD, JNS Kinase, Topical Administration Trial run by the NIAMS (Ruxolitinib 1.5% cream, vehicle cream)
Terminated
- Graft Versus Host Disease
- +2 more
- Ruxolitinib 1.5% cream
- vehicle cream
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 21, 2022
GVHD, GVHD, Acute-graft-versus-host Disease Trial in Canada, United States (Itolizumab, EQ001 Placebo)
Recruiting
- Graft Versus Host Disease
- +4 more
- Itolizumab
- EQ001 Placebo
-
Duarte, California
- +5 more
Jul 5, 2022
GVHD Trial in Ramat Gan (Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG))
Recruiting
- Graft Versus Host Disease
- Cyclophosphamide
- anti-human T-lymphocyte immunoglobulin (ATLG)
-
Ramat Gan, IsraelChaim Sheba Medical Center
May 4, 2022
Relationship Between "FODMAPs" and "GVHD"
Recruiting
- Graft Versus Host Disease
-
Suzhou, Jiangsu, China中国
Mar 26, 2022
GVHD, Leukemia, Lymphoma Trial in Duarte (biological, drug, procedure, radiation, other)
Active, not recruiting
- Graft Versus Host Disease
- +2 more
- rituximab
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
GVHD Trial (VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg)
Not yet recruiting
- Graft Versus Host Disease
- VM-001 1X10^6 cells/kg
- +4 more
- (no location specified)
Mar 2, 2022
GVHD Trial in Stanford ([18F]F-Ara-G)
Recruiting
- Graft Versus Host Disease
-
Stanford, CaliforniaStanford Hospital
Mar 7, 2022
GVHD Trial in Hackensack (Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose
Terminated
- Graft Versus Host Disease
- Cyclophosphamide and Sirolimus
- +3 more
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Feb 4, 2022
GVHD, Hematologic Malignancy, Cyclophosphamide Adverse Reaction Trial (Post-transplantation Cyclophosphamide at dose 25
Not yet recruiting
- Graft Versus Host Disease
- +2 more
- Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
- Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
- (no location specified)
Dec 17, 2021
The Skin Microbiome in Graft Versus Host Disease
Not yet recruiting
- Skin Microbiome
- +2 more
- Skin swabs
- +2 more
-
Basel, SwitzerlandDepartment of Dermatology; University Hospital Basel
Nov 3, 2021
